A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
This study is currently recruiting participants.
Verified January 2013 by Celgene Corporation
Study NCT00774345
Information provided by Celgene Corporation
First Received on October 16, 2008.
Last Updated on April 2, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
